Massachusetts Financial Services Co. MA Raises Position in Ascendis Pharma A/S (NASDAQ:ASND)

Massachusetts Financial Services Co. MA raised its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 9.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,866,986 shares of the biotechnology company’s stock after acquiring an additional 155,971 shares during the quarter. Massachusetts Financial Services Co. MA owned approximately 3.08% of Ascendis Pharma A/S worth $278,760,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ASND. Avoro Capital Advisors LLC grew its position in shares of Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after buying an additional 229,995 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Ascendis Pharma A/S by 23.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after purchasing an additional 336,976 shares during the period. Fred Alger Management LLC increased its stake in shares of Ascendis Pharma A/S by 65.0% during the second quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock valued at $41,879,000 after purchasing an additional 120,952 shares in the last quarter. Tri Locum Partners LP lifted its holdings in shares of Ascendis Pharma A/S by 102.1% during the second quarter. Tri Locum Partners LP now owns 227,762 shares of the biotechnology company’s stock valued at $31,062,000 after purchasing an additional 115,092 shares during the last quarter. Finally, Candriam S.C.A. boosted its position in shares of Ascendis Pharma A/S by 96.6% in the 2nd quarter. Candriam S.C.A. now owns 195,347 shares of the biotechnology company’s stock worth $26,640,000 after purchasing an additional 95,972 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Bank of America raised their price objective on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Jefferies Financial Group raised their price target on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a report on Tuesday, August 13th. Oppenheimer dropped their price target on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. Wedbush restated an “outperform” rating and set a $181.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Finally, Evercore ISI lifted their target price on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $191.77.

Ascendis Pharma A/S Price Performance

ASND stock opened at $129.81 on Friday. The company has a market cap of $7.87 billion, a P/E ratio of -16.07 and a beta of 0.66. Ascendis Pharma A/S has a 1 year low of $90.13 and a 1 year high of $161.00. The stock’s fifty day moving average price is $133.22 and its 200-day moving average price is $132.23.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. As a group, analysts expect that Ascendis Pharma A/S will post -7.45 earnings per share for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.